These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6703716)

  • 41. [History and significance of sensitivity test of anticancer drugs].
    Taguchi T
    Gan To Kagaku Ryoho; 1982 Apr; 9(4):570-4. PubMed ID: 7184413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Microdialysis: an in vivo approach for measuring drug delivery in oncology.
    Brunner M; Müller M
    Eur J Clin Pharmacol; 2002 Jul; 58(4):227-34. PubMed ID: 12136367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical research in cancer chemotherapy.
    Gross J
    Oncol Nurs Forum; 1986; 13(1):59-65. PubMed ID: 3632861
    [No Abstract]   [Full Text] [Related]  

  • 44. [Prerequisites for phase I and phase II clinical trials of drugs].
    Jaillon P; Dupuis B
    Arch Mal Coeur Vaiss; 1989 Oct; 82(10):1773-6. PubMed ID: 2512881
    [No Abstract]   [Full Text] [Related]  

  • 45. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improvement of phase III psychotropic drug trials by intensive phase II work.
    Klein DF
    Neuropsychopharmacology; 1991 Jun; 4(4):251-8; discussion 259-71. PubMed ID: 1867735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical trials of parenteral antineoplastic agents.
    Cusack G
    J Intraven Nurs; 1998; 21(6):339-43. PubMed ID: 10392099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical pharmacology in development of new anticancer agents].
    Sasaki Y
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():310-4. PubMed ID: 7986109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of anticancer medicinal products in man. CPMP Working Party on Efficacy of Medicinal Products.
    Pharmacol Toxicol; 1990 Nov; 67(5):454-8. PubMed ID: 2096391
    [No Abstract]   [Full Text] [Related]  

  • 50. [Methods for clinical study of antineoplastic drugs].
    Lichinitser MR
    Vopr Onkol; 1986; 32(8):93-8. PubMed ID: 3765515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Development of new substances in oncology. Many problems and some answers].
    Cavalli F
    Dtsch Med Wochenschr; 1980 Jun; 105(26):909-10. PubMed ID: 6996985
    [No Abstract]   [Full Text] [Related]  

  • 52. Rationale for anticancer drug dosing schedules.
    Reich SD
    Cancer Nurs; 1983 Dec; 6(6):465-7. PubMed ID: 6360342
    [No Abstract]   [Full Text] [Related]  

  • 53. New anticancer drugs.
    Recent Results Cancer Res; 1980; 70():1-229. PubMed ID: 6986640
    [No Abstract]   [Full Text] [Related]  

  • 54. [Clinical trial of protein anabolizing drugs].
    Therapie; 1973; 28(6):1093-100. PubMed ID: 4603410
    [No Abstract]   [Full Text] [Related]  

  • 55. A simulation study of the preclinical development of anticancer drugs.
    Gordon MH
    Cancer Chemother Rep 3; 1974 Sep; 5(1):65-78. PubMed ID: 4411758
    [No Abstract]   [Full Text] [Related]  

  • 56. Missing results might have rung warning bell over trial drug.
    Pearson H
    Nature; 2006 Oct; 443(7113):730-1. PubMed ID: 17051171
    [No Abstract]   [Full Text] [Related]  

  • 57. SOP 01: Clinical investigations in CESAR.
    Onkologie; 2003 Oct; 26 Suppl 6():1-4. PubMed ID: 23570177
    [No Abstract]   [Full Text] [Related]  

  • 58. Guidance for development of chemopreventive agents.
    Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
    J Cell Biochem Suppl; 1994; 20():25-31. PubMed ID: 7616748
    [No Abstract]   [Full Text] [Related]  

  • 59. How drugs act. 30. The safety of drugs.
    Smith SE
    Nurs Times; 1976 Jan; 72(3):114-5. PubMed ID: 1107962
    [No Abstract]   [Full Text] [Related]  

  • 60. Introduction and use of investigational anticancer agents in Australia. First progress report. Anticancer Subcommittee of the Australian Drug Evaluation Committee.
    Med J Aust; 1984 Aug; 141(4):237-9. PubMed ID: 6482764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.